Literature DB >> 2054267

Measurement of glomerular function during cisplatin therapy.

D G Waller1, L Juer, J S Fleming.   

Abstract

1. Creatinine-based methods for measuring glomerular filtration rate (GFR) were compared with the plasma clearance of 99mTc DTPA as an accurate index of GFR in patients prior to and during cisplatin therapy. 2. Measured creatinine clearances using either unsupervised 24 h or supervised 4 h collections correlated less well with the reference GFR than did predicted creatinine clearances derived from serum creatinine using formulae or a nomogram. 3. Predicted creatinine clearance appears to be at least as sensitive as measured creatinine clearance for screening GFR in patients receiving cisplatin. However, owing to the inherent inaccuracy in any creatinine-based method, if the prediction is within 20% of the value at which dose reduction of cisplatin is considered, an isotopically determined GFR should be carried out to optimise dosage adjustments.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2054267      PMCID: PMC1368352          DOI: 10.1111/j.1365-2125.1991.tb05529.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  13 in total

1.  Urinary clearance of 113m In-DTPA and 99mTc-(Sn)DTPA measured by external arm counting.

Authors:  M A Macleod; W F Sampson; A S Houston
Journal:  Urol Res       Date:  1977

2.  Time to scrap creatinine clearance?

Authors:  R Gabriel
Journal:  Br Med J (Clin Res Ed)       Date:  1986-11-01

Review 3.  Use of serum creatinine concentrations to determine renal function.

Authors:  T D Bjornsson
Journal:  Clin Pharmacokinet       Date:  1979 May-Jun       Impact factor: 6.447

4.  Clinical value of the creatinine clearance before the administration of chemotherapy with cisplatin.

Authors:  E Davila; L B Gardner
Journal:  Cancer       Date:  1987-07-15       Impact factor: 6.860

5.  Some effects of combination chemotherapy with cis-platinum on renal function in patients with nonseminomatous testicular carcinoma.

Authors:  S Meijer; D T Sleijfer; N H Mulder; W J Sluiter; J Marrink; H S Koops; T M Brouwers; J Oldhoff; G K van der Hem; E Mandema
Journal:  Cancer       Date:  1983-06-01       Impact factor: 6.860

Review 6.  Cisplatin nephrotoxicity: a summary of preventative interventions.

Authors:  R S Finley; C L Fortner; W R Grove
Journal:  Drug Intell Clin Pharm       Date:  1985-05

7.  Simultaneous measurement of renal clearance and plasma clearance of 99mTc-labelled diethylenetriaminepenta-acetate, 51Cr-labelled ethylenediaminetetra-acetate and inulin in man.

Authors:  M Rehling; M L Møller; B Thamdrup; J O Lund; J Trap-Jensen
Journal:  Clin Sci (Lond)       Date:  1984-05       Impact factor: 6.124

8.  Influence of range of renal function and liver disease on predictability of creatinine clearance.

Authors:  J H Hull; L J Hak; G G Koch; W A Wargin; S L Chi; A M Mattocks
Journal:  Clin Pharmacol Ther       Date:  1981-04       Impact factor: 6.875

9.  Inadequacy of predicted creatinine clearance as guide to chemotherapy.

Authors:  D F McDermott; A Galindo; R L Sherman; E A Jaffe; M Coleman; M W Pasmantier
Journal:  Cancer Treat Rep       Date:  1987-11

10.  Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose.

Authors:  G Daugaard; N Rossing; M Rørth
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.